presented by Bruce Cheson, MD

presented by Irene Ghobrial, MD

presented by Aviva Asnis-Alibozek, PA-C

A Novel High-Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine, and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: A Phase I-II Study on 44 Patients

presented by Guiseppe Visani, MD

presented by James R. Berenson, MD

Bendamustine Induces Higher Remission Rates, Prolongs Progression-Free Survival as well as Time to Next Treatment, and Improves Overall Survival for Patients in Complete Remission without Compromising Quality of Life when Compared to Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia

presented by Wolfgang Ulrich Knauf, MD

presented by Farhad Ravandi, MD

presented by Farhad Ravandi, MD

presented by Farhad Ravandi, MD

presented by Mitchell R. Smith, MD, PhD

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine: Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

presented by Steven Stilgenbauer, MD

A Population-Based Study in Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported in Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry in the United States Between 1992-2007

presented by Martin S. Tallman, MD

Down-Regulation of Signal Transducer and Activator of Transcription 3 Enhances Acute Myeloid Leukemia–Derived Dendritic Cell Function

presented by Meir Wetzler, MD